EUVIMEDEUVIMED entdecken
Crossref

The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis

Riccardo Laudicella iD, Greta Celesti iD, Matteo Bauckneht iD, Agatino Micali, Federica Midili, Antonio Bucca, Victorian M Ferro iD, Michela Piergentili, Giorgia Ricciardello, Anna Brogna, Benedetta Pagano, Sergio Baldari und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5774-5781

DOI: 10.1007/s00259-026-07927-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 20.05.2026. Verfasst von Riccardo Laudicella und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. rlaudicella@…. Hauptthemen laut MEDLINE: Dipeptides, Single Photon Emission Computed Tomography Computed Tomography, Lutetium, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: [¹⁷⁷Lu]Lu-PSMA RLT represents an effective option for advanced mCRPC. SPECT/CT allows the assessment of biodistribution and lesion-level tracer accumulation. We aimed to determine whether semiquantitative RLT SPECT/CT parameters could predict response on a lesion level. METHODS: We retrospectively considered consecutive mCRPC patients who, between February 2022 and January 2026, received minimum two [¹⁷⁷Lu]Lu-PSMA-617 cycles at Messina and Genova Universities, with SPECT/CT at the 1st RLT, including whole PSMA-positive disease. Each [¹⁷⁷Lu]Lu-PSMA-617-positive lesion was semiautomatically segmented using MIM through a 40% threshold to extract SUVmax, SUVmean, Total Lesion Volume (TLV), and Total Lesion Activity (TLA=SUVmean×TLV). Each lesion's semiquantitative parameter was correlated with the single-lesion response at the last RLT cycle, classified as progressive or non-progressive (complete/partial response, stable disease) according to cut-offs from qualitative RECIP 1.0 and quantitative PPP criteria. ROC curves were used to determine the best cutoffs. RESULTS: We included 23 mCRPC patients for a total of 290 lesions: 249 osteomedullary, 34 lymph nodal, and 7 visceral. At the last cycle, 60 out of 290 lesions progressed, while 230 out of 290 remained stable/responded to RLT. 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters were significantly higher in non-PD than in PD lesions (p < 0.001 for TLA, SUVmax, SUVmean; p = 0.008 for TLV). On ROC analysis, TLA reached an AUC of 0.854 (best cut-off = 61.7), SUVmax 0.843 (best cut-off = 11.8), SUVmean 0.838 (best cut-off = 6), and TLV 0.612 (best cut-off = 7.05mL), respectively. CONCLUSION: Our preliminary findings suggest that 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters, especially when reflecting PSMA-expression, may serve as promising early predictors of the single-lesion response to RLT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesSingle Photon Emission Computed Tomography Computed TomographyLutetiumHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantHumansRetrospective StudiesMaleAgedMiddle AgedRadioisotopesAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

177LutetiumProstate cancerProstate-specific membrane antigenRadioligand therapySUVSingle-photon emission computed tomography

Substanzen

DipeptidesLutetiumHeterocyclic Compounds, 1-RingLutetium-177PSMA-617RadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. rlaudicella@unime.it.
  • Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
  • IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
  • Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
  • Health Physics Unit, Messina University Hospital G. Martino, Messina, Italy.
  • Health Physics School of Specialization, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.

ORCID-Profile: Riccardo Laudicella, Greta Celesti, Matteo Bauckneht, Victorian M Ferro, Irene A Burger

Zitieren

APA

Laudicella, R., Celesti, G., Bauckneht, M., Micali, A., Midili, F., Bucca, A., Ferro, V. M., Piergentili, M., Ricciardello, G., Brogna, A., Pagano, B., Baldari, S., Burger, I. A., & Minutoli, F. (2026). The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5774-5781. https://doi.org/10.1007/s00259-026-07927-x

Vancouver

Laudicella R, Celesti G, Bauckneht M, Micali A, Midili F, Bucca A, et al. The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5774-5781. doi:10.1007/s00259-026-07927-x

BibTeX
@article{Laudicella2026,
  author = {Laudicella, Riccardo and Celesti, Greta and Bauckneht, Matteo and Micali, Agatino and Midili, Federica and Bucca, Antonio and Ferro, Victorian M and Piergentili, Michela and Ricciardello, Giorgia and Brogna, Anna and Pagano, Benedetta and Baldari, Sergio and Burger, Irene A and Minutoli, Fabio},
  title = {The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {10},
  pages = {5774--5781},
  doi = {10.1007/s00259-026-07927-x}
}
Kostenlos starten →